Biofarm registered a 17 pct increase in turnover for the first half of 2023, compared to the same period of the previous year, and the net profit reached RON 50.1 million, registering an advance of approximately 15 pct compared to the same period last year.
In terms of EBITDA, the company reports an increase of 3 pct, reaching a level of RON 61.2 million, agerpres reports.
In the first semester of the year, Biofarm ranks 2nd in Consumer Healthcare (CHC), according to the number of units sold.
Biofarm has in its portfolio a drug factory with an area of over 10,000 square meters and four production streams - tablets/film-coated tablets/dragees, soft capsules, solutions and syrups. The investment, which has so far exceeded EUR 44 million, has tripled production capacity and aligns with the company's strategic objectives: portfolio development through line extensions, new product launches and expansion on foreign markets.
Biofarm is one of the first Romanian producers of medicines and food supplements, the company having 100 years of activity